Kaken Pharmaceutical will hand Alumis $40 million in the near term for the rights to develop a late-stage tyrosine kinase 2 ...
For more information, visit www.alumis.com. About Kaken Pharmaceutical Kaken Pharmaceutical is a specialty pharmaceutical company in Japan with strong experience in developing and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback